PharmX Technologies Statistics
Want to see AU:PHX full AI Analyst Report?
PharmX Technologies (PHX) Stock Statistics & Valuation Metrics
Total Valuation
PharmX Technologies has a market cap or net worth of AUD 46.13M. The enterprise value is AUD 79.67M.
- Market Cap
- AUD 46.13M
- Enterprise Value
- AUD 79.67M
Share Statistics
PharmX Technologies has 668,618,650 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 668,618,650
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
PharmX Technologies’s return on equity (ROE) is -0.08 and return on invested capital (ROIC) is -7.79%.
- Return on Equity (ROE)
- -0.08
- Return on Assets (ROA)
- -0.07
- Return on Invested Capital (ROIC)
- -7.79%
- Return on Capital Employed (ROCE)
- -0.09
- Revenue Per Employee
- 846.33K
- Profits Per Employee
- -202.89K
- Employee Count
- 9
- Asset Turnover
- 0.28
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of PharmX Technologies is -16.56. PharmX Technologies’s PEG ratio is 0.16.
- PE Ratio
- -16.56
- PS Ratio
- 3.80
- PB Ratio
- 1.75
- Price to FCF
- 39.47
- Price to Operating Cash Flow
- 36.44
- PEG Ratio
- 0.16
Income Statement
In the last 12 months, PharmX Technologies had revenue of 7.62M and earned -1.83M in profits. Earnings per share was -0.00.
- Revenue
- 7.62M
- Gross Profit
- -70.00K
- Operating Income
- -2.09M
- Pretax Income
- -2.01M
- Net Income
- -1.83M
- EBITDA
- -532.00K
- Earnings Per Share (EPS)
- -0.00
Cash Flow
In the last 12 months, operating cash flow was 1.12M and capital expenditures -20,000, giving a free cash flow of 1.10M billion.
- Operating Cash Flow
- 1.12M
- Free Cash Flow
- 1.10M
- Free Cash Flow per Share
- 0.00
Dividends & Yields
PharmX Technologies pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.39%
- Earnings Yield
- -4.21%
Stock Price Statistics
- Beta
- 0.65
- 52-Week Price Change
- -54.00%
- 50-Day Moving Average
- 0.08
- 200-Day Moving Average
- 0.10
- Relative Strength Index (RSI)
- 43.73
- Average Volume (3m)
- 578.89K
Important Dates
PharmX Technologies upcoming earnings date is Feb 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 26, 2026
- Next Earnings Date
- Feb 25, 2027
- Ex-Dividend Date
- ―
Financial Position
PharmX Technologies as a current ratio of 2.33, with Debt / Equity ratio of 2.32%
- Current Ratio
- 2.33
- Quick Ratio
- 2.33
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 3.82
- Interest Coverage Ratio
- -47.50
Taxes
In the past 12 months, PharmX Technologies has paid -188.00K in taxes.
- Income Tax
- -188.00K
- Effective Tax Rate
- 0.09
Enterprise Valuation
PharmX Technologies EV to EBITDA ratio is 178.56, with an EV/FCF ratio of 40.06.
- EV to Sales
- 3.86
- EV to EBITDA
- 178.56
- EV to Free Cash Flow
- 40.06
- EV to Operating Cash Flow
- 39.34
Balance Sheet
PharmX Technologies has AUD 2.57M in cash and marketable securities with AUD 540.00K in debt, giving a net cash position of AUD 2.03M billion.
- Cash & Marketable Securities
- AUD 2.57M
- Total Debt
- AUD 540.00K
- Net Cash
- AUD 2.03M
- Net Cash Per Share
- AUD 0.00
- Tangible Book Value Per Share
- AUD 0.02
Margins
Gross margin is 8.05%, with operating margin of -18.29%, and net profit margin of -15.98%.
- Gross Margin
- 8.05%
- Operating Margin
- -18.29%
- Pretax Margin
- -17.63%
- Net Profit Margin
- -15.98%
- EBITDA Margin
- 2.16%
- EBIT Margin
- -18.29%
Analyst Forecast
The average price target for PharmX Technologies is AUD 0.16, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- AUD 0.16
- Price Target Upside
- 124.64% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- 4.06%
- EPS Growth Forecast
- -625.00%
Scores
- Smart Score
- 7
- AI Score
- 45

